[Alizapride versus placebo in premedication for esophagogastroduodenoscopy. Double-blind clinical study. Experimental research in vitro].
The pronounced antiemetic properties of Alizapride, one of the new azimidobenzamides suggested the assessment of its efficacy on 40 patients due for oesophagogastroduodenoscopy. The drug proved highly satisfactory as premedication for the examination, significantly inhibiting vomiting and stomach wall tone during the examination as was indicated by in vitro studies.
Cosentino
F
F
Prato
A
A
Laudani
A
A
Percolla
S
S
Franco
S
S
Veroux
P F
PF
Immè
A
A
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004384:Duodenoscopy / Q000009:adverse effects; D004724:Endoscopy / Q000009:adverse effects*; D004945:Esophagoscopy / Q000009:adverse effects; D005769:Gastrointestinal Motility / Q000187:drug effects*; D005773:Gastroscopy / Q000009:adverse effects; D006801:Humans; D066298:In Vitro Techniques; D011292:Premedication; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*
D000932:Antiemetics; D011759:Pyrrolidines; C033968:alizapride
Alizapride vs. placebo nella premedicazione all'esofagogastroduodenoscopia. Studio clinico in doppio cieco. Ricerche sperimentali in vitro.